Junning Ma | Cell Surface Receptors | Best Research Article Award

Dr. Junning Ma | Cell Surface Receptors | Best Research Article Award

Zhejiang University | China

Dr. Junning Ma has developed a multidisciplinary portfolio spanning neurosurgery, neural engineering, biomaterials, and nanomedicine. Their work integrates neural stem cell biology, targeted drug delivery, and tumor microenvironment modulation to create innovative therapeutic strategies for brain diseases. They have conducted advanced postdoctoral and doctoral research at major institutions, contributing to National Natural Science Foundation of China (NSFC) Youth Fund projects and multiple US-funded NIH and AHA grants. Their research focuses on biomimetic nanocarriers, including cell membrane-coated nanoparticles, PLGA-based delivery systems, and fusion-membrane technologies designed for precision therapy of glioma, pituitary adenoma, and ischemic stroke.

Key projects include engineered neural stem cell membrane-coated nanoparticles for stroke targeting, biomimetic nanoplatforms for cancer immunotherapy, and tumor microenvironment–responsive delivery systems. They have also contributed to studies on neuromodulation, neurotrophic factor-based therapy, neural stem cell transplantation, and photothrombotic stroke models. Their publication record includes high-impact journals such as Materials Today Bio, Biomaterials, Nano Letters, Small, and Cell Reports Physical Science, covering topics like vascular-targeting nanoclusters, polyphenol nanoparticles, and membrane-engineered carriers.

Overall, their research advances translational nanomedicine and regenerative neuroscience, with an emphasis on targeted therapies capable of overcoming the challenges of brain tumor heterogeneity, the blood–brain barrier, and ischemic neural injury.

Profiles: Scopus | Orcid

Featured Publications: 

Ma, J., Win, Y., Xiaojian, Z., et al. (2023). Enhanced EPR effects by folliculostellate cell membrane–coated nanoparticles on invasive pituitary adenoma. Materials Today Bio.

Ma, J., Dai, L., Jianbo, Y., et al. (2023). Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology. Biomaterials.

Ma, J., Liu, F., Wendy, C., et al. (2020). Co-presentation of tumor antigens with costimulation via biomimetic nanoparticles for effective cancer immunotherapy. Nano Letters.

Ma, J., Zhang, S., Jun, L., et al. (2019). Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membranes of engineered neural stem cells. Small.

Ilaria Cossu | Immunology Cellular Interactions | Research Excellence Award

Ms. Ilaria Cossu | Immunology Cellular Interactions | Research Excellence Award

University of Sassari | Italy

Ilaria Cossu is a motivated PhD candidate in Life Sciences and Biotechnologies with a specialization in Microbiology and Immunology. Their work focuses on understanding the role of human endogenous retroviruses (HERVs) in cancer, integrating molecular biology, immunology, and virology approaches to explore how retroviral elements may influence tumorigenesis. Their doctoral project involves conducting indirect ELISA assays, maintaining and analyzing cell cultures, processing blood samples, performing RNA extraction and reverse transcription, and carrying out quantitative PCR for gene expression profiling. The researcher is actively engaged in experimental design, data analysis, scientific writing, and collaborative research activities at both national and international levels.

Prior academic training includes Master’s and Bachelor’s degrees in Biology, each completed with top distinction, and research internships in microbiology, virology, and biochemistry laboratories. These experiences provided hands-on expertise in electrophoretic methods such as cellulose acetate electrophoresis, C-PAGE, fluorescent 2-aminoacridone probe (FACE) analysis, and SDS-PAGE, contributing to a solid foundation in protein and nucleic acid characterization. Their current research aims to advance understanding of retroviral contributions to cancer biology and supports the development of innovative molecular approaches for disease investigation and potential therapeutic insights.

Profile: Scopus

Featured Publications:

Cossu, I., Ruberto, S., Filippi, E., Simula, E. R., Noli, M., Mottula, A., & others. (2025). HERV-K envelope induces a humoral response in Non-Hodgkin lymphoma patients. Current Microbiology, 82(12), 574.

Jasemi, S., Molicotti, P., Fais, M., Cossu, I., Simula, E. R., Sechi, L. A., & others. (2025). Biological mechanisms of enterotoxigenic Bacteroides fragilis toxin: Linking inflammation, colorectal cancer, and clinical implications. Toxins, 17(6), 305.

Simula, E. R., Jasemi, S., Cossu, D., Fais, M., Cossu, I., Chessa, V., & others. (2025). Human endogenous retroviruses as novel therapeutic targets in neurodegenerative disorders. Vaccines, 13(4), 415. h

Ruberto, S., Santovito, A., Caviglia, G. P., Noli, M., Cossu, D., Ribaldone, D. G., & others. (2025). Mycobacterium avium subsp. paratuberculosis and human endogenous retrovirus in Italian patients with inflammatory bowel disease and irritable bowel syndrome. Immunology.

Ran Wang | Pulmonary Hypertension | Best Researcher Award

Prof. Dr. Ran Wang | Pulmonary Hypertension | Best Researcher Award

First Affiliated Hospital of Anhui Medical University | China

Dr. Ran Wang is an accomplished respiratory medicine researcher whose work has significantly advanced the understanding of pulmonary hypertension and chronic obstructive pulmonary disease (COPD). With more than two decades of clinical and scientific experience, he has extensively investigated the molecular mechanisms underlying hypoxic pulmonary hypertension and COPD pathogenesis. His research has contributed to improved insights into vascular remodeling, inflammatory signaling, and pulmonary vascular resistance, helping to strengthen the scientific basis for future diagnostic and therapeutic strategies.

He has successfully led multiple high-impact research projects, including two funded by the National Natural Science Foundation and three additional provincial-level studies. His work spans basic, translational, and clinical domains, integrating experimental models with patient-centered research to address key challenges in pulmonary vascular diseases. He has authored or co-authored 59 peer-reviewed journal articles, including over 50 SCI-indexed publications and more than 20 as first or corresponding author. His research outputs include four patents related to respiratory disease mechanisms and clinical application innovations.

In addition to his scholarly publications, he serves on editorial boards of leading journals such as Journal of Cancer Research and Clinical Oncology, BMC Pulmonary Medicine, and Cancer Control, contributing to the advancement of scientific discourse in respiratory and cancer research.

Profile: Scopus

Featured Publications:

  • Han, R., Guan, Y., Li, P., Tang, M., Fei, G., Zeng, D., & Wang, R. (2025). Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study. Journal of Infection and Public Health, 18(12), 102987.

  • Liu, Y., Wang, R., & Jiang, T. (2025). RNA-binding proteins as a molecular link between COPD and pulmonary hypertension. International Journal of Medical Sciences, 22(8), 1979–1991.

  • Rao, B., Wang, D., Yang, M., … et al. (2025). Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: A multicenter, retrospective, cohort study. BMC Infectious Diseases, 25, 275.

 

 

 

Wan Wan Lin | Inflammation | Best Researcher Award

Prof. Wan Wan Lin | Inflammation | Best Researcher Award

Department of Pharmacology, College of Medicine, NTU | Taiwan

Dr. Wan-Wan Lin is a leading researcher in the fields of pharmacology and immunology, with a strong focus on cellular signaling and innate immune mechanisms. Her work has significantly advanced understanding of signal transduction pathways and their regulation of inflammation and cell death. She has made notable contributions to the study of pattern recognition receptors, inflammasomes, and cytokine-mediated immune responses, particularly in the context of oxidative stress and mitochondrial function. Dr. Lin’s research explores how mitochondrial dynamics and redox balance influence inflammatory signaling and programmed cell death, providing key insights into the molecular basis of immune regulation and inflammatory diseases. Her studies have also shed light on the crosstalk between cellular stress responses and immune activation, offering potential therapeutic targets for controlling excessive inflammation and tissue damage. Recognized for her excellence in research, Dr. Lin has received multiple national awards and continues to contribute to the advancement of pharmacological sciences through her editorial and academic roles. Her integrative approach bridges pharmacology, immunology, and cell biology, driving innovations in the understanding of molecular mechanisms underlying inflammation and innate immunity.

Profile: Orcid

Featured Publications:

Lin, W.-W., Lee, C.-Y., Tsai, M.-C., & Tsaur, M.-L. (1985). Pharmacological study on angusticeps-type toxins from mamba snake venoms. Journal of Pharmacology and Experimental Therapeutics, 233, 491–498.

Lin, W.-W., Chang, P.-L., Lee, C.-Y., & Joubert, F. J. (1987). Pharmacological study on phospholipases A₂ isolated from Naja mossambica mossambica venom. Proceedings of the National Science Council, Republic of China B, 11, 155–163.

Lin, W.-W., Lee, C.-Y., & Burnett, J. W. (1988). Effect of sea nettle (Chrysaora quinquecirrha) venom on isolated rat aorta. Toxicon, 26, 1209–1212.

Chiou, S.-H., Lin, W.-W., & Chang, W.-P. (1989). Sequence characterization of venom toxins from Thailand cobra. International Journal of Peptide and Protein Research, 34, 148–152.

Lee, C.-Y., Lin, W.-W., Chen, Y.-M., & Lee, S.-Y. (1989). Is direct cardiotoxicity the primary cause of death following intravenous injection of the basic phospholipase A₂ from Naja nigricollis venom? Acta Physiologica et Pharmacologica Latinoamericana, 39, 383–391.

Lee, C.-Y., & Lin, W.-W. (1989). Two subtypes of acetylcholinesterase isoenzymes distinguishable by Angusticeps-type toxin F7. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology and Toxicology, 92, 279–281.

Lin, W.-W., Lee, C.-Y., & Chuang, D.-M. (1989). Cross-desensitization of endothelin- and sarafotoxin-induced phosphoinositide turnover in neurons. European Journal of Pharmacology, 166, 581–582.

Lin, W.-W., Chen, Y.-M., Lee, S.-Y., Nishio, H., Kimura, T., Sakakibara, S., & Lee, C.-Y. (1990). Cardiovascular effects of two disulfide analogues of sarafotoxin S6b. Toxicon, 28, 911–923.

Lin, W.-W., Lee, C.-Y., Yasumoto, T., & Chuang, D.-M. (1990). Maitotoxin induces phosphoinositide turnover and modulates glutamatergic and muscarinic cholinergic receptor function in cultured cerebellar neurons. Journal of Neurochemistry, 55, 1563–1568.

Lin, W.-W., & Lee, C.-Y. (1990). Biphasic effects of endothelin in the guinea-pig ileum. European Journal of Pharmacology, 176, 57–62.

Mohamed Dammak | Cell Structure Analysis | Best Academic Researcher Award

Prof. Dr. Mohamed Dammak | Cell Structure Analysis | Best Academic Researcher Award

Faculty of Sciences of Sfax | Tunisia

Professor Mohamed Dammak is a distinguished researcher in the field of chemistry, recognized for his significant contributions to materials science, solid-state chemistry, and nanomaterials. His research primarily focuses on the synthesis, structural characterization, and optical properties of functional materials, including luminescent phosphors, glass ceramics, and doped oxide systems. He has extensively investigated rare-earth-doped materials for photonic and optoelectronic applications, contributing valuable insights into energy transfer mechanisms and material stability under various conditions. Professor Dammak’s scholarly output includes numerous publications in high-impact journals indexed in SCI and Scopus, reflecting his consistent pursuit of scientific excellence. With over 1,100 citations and an h-index of 17, his work has had a measurable influence on contemporary research in materials chemistry. He has also participated in national and international research collaborations, enhancing cross-disciplinary approaches to the development of advanced materials with optical and structural functionalities. Through his academic leadership and commitment to innovation, Professor Dammak continues to advance the understanding and application of inorganic and functional materials, bridging the gap between fundamental research and technological development in the field of chemistry.

Profile: Scopus

Featured Publications:

Dammak, M.*, Abdelmoula, N., Cheikhrouhou-Koubaa, W., & Cheikhrouhou, A. (2021). Short-range magnetic behavior in manganites La₀.₉₃K₀.₀₇Mn₁₋ₓCuₓO₃ (0.0 ≤ x ≤ 0.09) above the Curie temperature. Journal of Physics D: Applied Physics, 54(32), 325002. https://doi.org/10.1088/1361-6463/ac015c

 

Tong Ming Liu | Stem Cell Research | Best Researcher Award

Dr. Tong Ming Liu |  Stem Cell Research | Best Researcher Award

Institute of Molecular and Cell Biology | Singapore

Dr. Tong Ming Liu’s research focuses on advancing gene and cell therapy through innovative studies on human mesenchymal stem cells (hMSCs) and induced pluripotent stem cells (iPSCs). His work explores the mechanisms governing mesenchymal stem cell stemness, potency, and ageing, with the goal of improving the therapeutic efficacy and manufacturing quality of MSC-based treatments. A central aspect of his research is identifying and characterizing critical quality attributes (CQAs) in MSC manufacturing to ensure consistent and safe clinical applications. Dr. Liu also investigates disease modeling of bone and cartilage disorders using iPSC-derived MSCs to facilitate drug screening and gene correction strategies. His recent projects include the development of optimized media for iPSC, iPSC-MSC, and MSC culture, as well as identifying novel biomarkers to select high-quality MSCs for regenerative medicine. Through his studies, he aims to enhance the scalability, functionality, and translational potential of stem cell therapies. His findings have been recognized in scientific forums such as the EVANTICA Symposium and Singapore Cell and Gene Therapy Conference, underscoring his contribution to the development of efficient MSC-derived extracellular vesicle (MSC-EV) optimization and regenerative therapy innovations.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Liu, T. M.*, Tew, W., Yang, Z., Lim, B., Hui, J. H. P., Lee, E. H., Loh, Y.-H., & Cool, S. (2025). Understanding the molecular basis of mesenchymal stem cell stemness: Implications for clinical applications. Cell Death & Disease, 16(1), 778.

Liu, T. M.* (2025). MSC-EVs: Pioneering the next generation of biomedical applications. World Journal of Stem Cells, 17(6), 108197.

Liu, T. M.*, & Wu, Y. (2023). Advancing gene and cell therapy using human mesenchymal stem cells. Frontiers in Cell and Developmental Biology, 11, 1294460.

Shou, Y., Liu, L., Le, Z., Lee, K. L., Li, X., Koh, D. Z., Wang, Y., Liu, T. M., Yang, Z., Lim, C. T., Cheung, C., & Tay, A. (2023). Mechano-responsive hydrogel for directing stem cell manufacturing and therapy. Bioactive Materials, 24, 387–400.

Liu, T. M.* (2021). Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine. World Journal of Stem Cells, 13(12), 1826–1844.

Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., Ng, S. K., Yang, Y. S., Lezhava, A., Hui, J., Oh, S., & Cool, S. M. (2022). Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Cytotherapy, 24(5), 456–472.

Liu, T. M.*, Yildirim, E. D., Li, P., Fang, H. T., Denslin, V., Kumar, V., Loh, Y.-H., Lee, E. H., Cool, S. M., Teh, B. T., Hui, J. H., Lim, B., & Shyh-Chang, N. (2020). Ascorbate and iron are required for the specification and long-term self-renewal of human skeletal mesenchymal stromal cells. Stem Cell Reports, 14(2), 210–225.

Hamidreza Mohammadi | Toxicology and Pharmacology | Best Researcher Award

Prof. Hamidreza Mohammadi | Toxicology and Pharmacology | Best Researcher Award

Mazandaran University of Medical Sciences, Sari, Iran

Dr. Hamidreza Mohammadi is a researcher specializing in toxicology, pharmacology, and nanomedicine, with extensive work focused on the toxicological and therapeutic applications of nanomaterials. His research spans multiple domains including nanotoxicology, polymer therapeutics, clinical and food toxicology, and the development of safer nanopharmaceuticals. He has contributed to advancing the understanding of how engineered nanomaterials interact with biological systems, emphasizing risk assessment, cellular mechanisms of toxicity, and strategies for biocompatibility improvement. Dr. Mohammadi’s studies also explore the design of polymer-based drug delivery systems with enhanced therapeutic efficacy and reduced side effects. His work integrates experimental and applied toxicology to bridge laboratory research with clinical practice, contributing to public health and safety in pharmacological sciences. With interdisciplinary expertise covering both environmental and clinical toxicology, his research aligns with global priorities in nanomedicine innovation and toxicological risk evaluation. His scholarly efforts continue to support the development of next-generation nanotherapeutics with optimized pharmacokinetics and minimized toxic responses, reinforcing the importance of safe and sustainable nanotechnology in medical and pharmaceutical applications.

Profile: Orcid

Featured Publications:

Mokhtari Azad, T., Mohammadi, H., Moosavi, A., Saadatmand, Z., & Nategh, R. (2004). Influenza surveillance in the Islamic Republic of Iran from 1991 to 2001. Eastern Mediterranean Health Journal, 10(3), 315–321.

Cheraghali, A. M., Mohammadi, H. R., Amirahmadi, M., Yazdanpanah, H., Abouhossain, G., & Zamanian, F. (2005). Incidence of patulin contamination in apple juice produced in Iran. Food Control, 16(2), 165–167.

Shafiee, H., Mohammadi, H., Rezayat, S. M., Hosseini, A., Baeeri, M., & Hassani, S. (2010). Prevention of malathion-induced depletion of cardiac cells mitochondrial energy and free radical damage by a magnetic magnesium-carrying nanoparticle. Toxicology Mechanisms and Methods, 20(9), 538–543.

Mohammadi, H., Karimi, G., Rezayat, S. M., Reza, A., Shafiee, H., & Nikfar, S. (2011). Benefit of nanocarrier of magnetic magnesium in rat malathion-induced toxicity and cardiac failure using non-invasive monitoring of electrocardiogram and blood pressure. Toxicology and Industrial Health, 27(5), 417–429.

Soltani, M., Shetab-Boushehri, S. F., Mohammadi, H., & Shetab-Boushehri, S. V. (2013). Proposing boric acid as an antidote for aluminium phosphide poisoning by investigation of the chemical reaction between boric acid and phosphine. Journal of Medical Hypotheses and Ideas, 7(1), 21–24.

Kavosh Zandsalimi | Skin Regeneration | Best Researcher Award

Dr. Kavosh Zandsalimi | Skin Regeneration | Best Researcher Award

Medical Laser Research Center, Yara Institute, ACECR, Tehran | Iran

Dr. Kavosh Zandsalimi is a biomedical engineer specializing in biomaterials and tissue repair technologies, with extensive expertise in the design, synthesis, and characterization of advanced biomaterials for biomedical applications. His research focuses on hydrogels, sponges, films, and micro/nanofibers, with particular emphasis on drug delivery systems, including hydrogels, nanofibers, microspheres, and metal-organic frameworks (MOFs). He has developed and optimized strategies for evaluating biomaterials in vitro, including cytotoxicity assessment, and antibacterial and anti-inflammatory efficacy. Dr. Zandsalimi’s work integrates nanomaterials synthesis with biomedical applications, aiming to enhance wound healing and tissue repair outcomes. He has successfully led projects that bridge fundamental research with translational applications, securing competitive research funding and mentoring teams in national and international innovation competitions. His research contributions extend to the development of protocols aligned with Good Laboratory Practice (GLP) and cleanroom standards, ensuring high-quality, reproducible results. Additionally, he has contributed to training programs on laboratory safety, biomaterials handling, and regulatory standards, reflecting his commitment to advancing both scientific knowledge and professional expertise in the biomedical engineering field.

Profiles: Google Scholar | Scopus

Featured Publications:

Heidari, B., Shams, S., Akbari, N., & Zandsalimi, K. (2025). Three-dimensionally decellularized human amniotic membrane scaffold: Structure, processing, and biological properties. Cell and Tissue Banking, 19(2), 2–47.

Karimi, M., Heidari, B., Jafary, H., & Zandsalimi, K. (2025). The quality and quantity of nanoparticles extracted from human adipose tissue derived-mesenchymal stem cells. Avicenna Journal of Medical Biotechnology, 17(3), 186–195.

Khorsandi, K., Hosseinzadeh, R., Esfahani, H., Zandsalimi, K., Shahidi, F. K., & Abrahamse, H. (2022). Accelerating skin regeneration and wound healing by controlled ROS from photodynamic treatment. Inflammation and Regeneration, 42(1), 40.

Talabani, R. M., Garib, B. T., Masaeli, R., Zandsalimi, K., & Ketabat, F. (2021). Biomineralization of three calcium silicate-based cements after implantation in rat subcutaneous tissue. Restorative Dentistry & Endodontics, 46(1).

Zandsalimi, K., & Akbari, B. (2021). Improving the mechanical properties of polyetheretherketone (PEEK) using organophilic montmorillonite for the manufacture of orthopedic and dental implants. In National Conference of Modern Materials (pp. 1–8).

Yi Zhang | Tumor Immunology | Best Researcher Award

Prof. Yi Zhang | Tumor Immunology | Best Researcher Award

The First Affiliated Hospital of Zhengzhou University | China

Prof. Yi Zhang is a globally recognized leader in genetically engineered cell therapy and translational immuno-oncology research. Over the past 36 years, he has made pioneering contributions to overcoming major barriers in cell therapy and advancing its clinical applications worldwide. His extensive research has produced 290 SCI-indexed publications, including 11 ESI top 1% highly cited papers, accumulating more than 14,000 citations and an h-index of 66. Prof. Zhang’s groundbreaking innovations include identifying the novel CAR-T therapeutic target CD276 for solid tumors, developing gene-editing technologies to reduce PD-1–mediated immunosuppression, and creating novel cytokines and culture protocols that enhance immune cell stemness and anti-tumor function. He has also led the development of CAR-T cells that normalize tumor vasculature and improve infiltration, significantly enhancing therapeutic efficacy. With 46 invention patents (17 authorized) and over 80 million yuan in technology transfers, his work bridges basic science and clinical application through an integrated “industry-university-research” platform. As principal investigator, he has directed more than 52 clinical trials—29 targeting solid tumors, the highest number globally—resulting in improved outcomes and even clinical cures for advanced cancer patients. His leadership in establishing national standards and safety protocols has also shaped the regulation and global best practices in cell therapy.

Profile: Orcid

Featured Publications:

Gao, Y., Liu, S., Huang, Y., Wang, H., Zhao, Y., Cui, X., Peng, Y., Li, F., & Zhang, Y. (2024, December 3). CAR T cells engineered to secrete IFNκ induce tumor ferroptosis via an IFNAR/STAT1/ACSL4 axis. Cancer Immunology Research.

Huang, Y., Cao, R., Wang, S., Chen, X., Ping, Y., & Zhang, Y. (2025, December 31). In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy. Human Vaccines & Immunotherapeutics.

Li, J., Wang, D., Zhang, Z., Sun, K., Lei, Q., Zhao, X., Huang, J., Wang, L., & Zhang, Y. (2025, June 1). Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer. The Journal of Immunology.

Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2025, March 5). Correction: Immunosenescence: A key player in cancer development. Journal of Hematology & Oncology.

Ping, Y., Fan, Q., & Zhang, Y. (2025, February). Modulating lipid metabolism improves tumor immunotherapy. Journal for ImmunoTherapy of Cancer.

Hu, W., Li, F., Liang, Y., Liu, S., Wang, S., Shen, C., Zhao, Y., Wang, H., & Zhang, Y. (2025, January). Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. Journal for ImmunoTherapy of Cancer.

Willa Hsueh | Immunometabolism | Best Researcher Award

Prof. Willa Hsueh | Immunometabolism | Best Researcher Award

The Ohio State University | United States

Dr. Willa Hsueh is a leading researcher in endocrinology, diabetes, and metabolism, with a career spanning several decades of pioneering contributions to hormone regulation and metabolic disease. Her early research provided key insights into renin biochemistry and aldosterone metabolism, particularly focusing on inactive “big renin” forms and their activation mechanisms in normal and pathological conditions such as diabetic nephropathy. Dr. Hsueh’s investigations have significantly advanced the understanding of the renin-angiotensin-aldosterone system (RAAS) and its role in blood pressure regulation, sodium balance, and endocrine disorders. Her studies explored adrenal physiology, steroid metabolism, and hormonal responses to physiological and pharmacological stimuli, laying the groundwork for later research on cardiovascular and metabolic dysfunctions in diabetes. Through her interdisciplinary approach combining endocrinology, nephrology, and metabolism, she has elucidated biochemical pathways linking hormonal imbalances to metabolic diseases. Dr. Hsueh continues to lead impactful research in diabetes and metabolic regulation, contributing to translational advancements that bridge molecular mechanisms with clinical applications for improved patient outcomes in endocrine and metabolic disorders.

Profiles: Scopus | Orcid

Featured Publications:

Hsueh, W. A., Boonjaren, S., Stein, J., Baehler, H. R., Osgood, R. W., Cohen, S., Yashon, D., & Ferris, T. (1974). Effect of plasma sodium concentration on diluting segment sodium reabsorption. Kidney International, 5(1), 1–11.

Johnson, K. R., Hsueh, W. A., Glusman, S. M., & Arnett, F. C. (1976). Fibrous myopathy: A rheumatic complication of drug abuse. Arthritis & Rheumatism, 19(5), 923–926.

Hsueh, W. A., & Hsu, T. H. (1978). Thyrotoxicosis in a patient with secondary hypothyroidism. Southern Medical Journal, 71(9), 1174–1177.

Hsueh, W. A., Luetscher, J. A., Carlson, E., & Grislis, G. (1978). Big renin in plasma of healthy subjects on high-sodium intake. The Lancet, 1(8077), 1281–1284.

Hsueh, W. A., Hsu, T. H., & Federman, D. D. (1978). Endocrine features of Klinefelter’s syndrome. Medicine, 57(5), 447–461.

Hsueh, W. A., Luetscher, J. A., Carlson, E., Grislis, G., Elbaum, D., & Chavarri, M. (1978). A comparison of cold and acid activation of big renin and of inactive renin in normal plasma. Journal of Clinical Endocrinology and Metabolism, 47(4), 792–799.